LEGEND BIOTECH CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 42.97 USD | -0.62% |
|
-5.06% | -28.59% |
| 01:47pm | Legend Biotech's Loss Narrows in Q1 as Revenue Surges | MT |
| 12:55pm | RBC Adjusts Price Target on Legend Biotech to $86 From $85 on Model Updates, Maintains Outperform Rating | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 545M | Sales 2025 * | 1.06B | Capitalization | 7.82B |
|---|---|---|---|---|---|
| Net income 2024 * | -310M | Net income 2025 * | -75M | EV / Sales 2024 * | 12.8 x |
| Net cash position 2024 * | 817M | Net cash position 2025 * | 822M | EV / Sales 2025 * | 6.62 x |
| P/E ratio 2024 * |
-43.6
x | P/E ratio 2025 * |
-155
x | Employees | 1,800 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99% |
More Fundamentals
* Assessed data
More news
Latest transcript on Legend Biotech Corporation
More recommendations
More press releases
More news
| 1 day | -0.62% | ||
| 1 week | -5.06% | ||
| Current month | -1.76% | ||
| 1 month | -18.80% | ||
| 3 months | -26.76% | ||
| 6 months | -33.52% | ||
| Current year | -28.59% |
1 week
42.21
46.89
1 month
42.0853.55
Current year
42.0870.13
1 year
42.0877.32
3 years
29.6177.32
5 years
23.4177.32
10 years
23.4177.32
| Managers | Title | Age | Since |
|---|---|---|---|
Ying Huang
CEO | Chief Executive Officer | 51 | 19-06-30 |
Lori Macomber
DFI | Director of Finance/CFO | 53 | 19-08-31 |
Tracy Luo
CTO | Chief Tech/Sci/R&D Officer | - | 18-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ying Huang
CEO | Chief Executive Officer | 51 | 19-06-30 |
Corazon Sanders
BRD | Director/Board Member | 67 | 20-04-30 |
Li Zhu
BRD | Director/Board Member | 74 | 20-11-22 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.08% | 4 M€ | -27.92% | ||
| 1.18% | 2 M€ | -14.14% | ||
| 0.99% | 2 M€ | -12.41% | - | |
| 0.95% | 11 M€ | -6.03% | - | |
| 0.58% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-13 | 42.97 | -0.62% | 1,328,091 |
| 24-05-10 | 43.24 | -5.01% | 887,591 |
| 24-05-09 | 45.52 | -0.44% | 528,848 |
| 24-05-08 | 45.72 | -0.59% | 586,301 |
| 24-05-07 | 45.99 | +1.61% | 689,704 |
Delayed Quote Nasdaq, May 13, 2024 at 04:00 pm EDT
More quotes
Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
42.97
USD
Average target price
86.27
USD
Spread / Average Target
+100.77%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -28.59% | 7.82B | |
| +5.66% | 111B | |
| +11.23% | 105B | |
| -2.68% | 21.93B | |
| -12.15% | 22.34B | |
| -5.61% | 18.59B | |
| -36.52% | 18.12B | |
| -10.09% | 16.96B | |
| +3.33% | 13.7B | |
| +36.58% | 12.45B |
- Stock Market
- Equities
- LEGN Stock